JP2021511042A5 - - Google Patents
Info
- Publication number
- JP2021511042A5 JP2021511042A5 JP2020539274A JP2020539274A JP2021511042A5 JP 2021511042 A5 JP2021511042 A5 JP 2021511042A5 JP 2020539274 A JP2020539274 A JP 2020539274A JP 2020539274 A JP2020539274 A JP 2020539274A JP 2021511042 A5 JP2021511042 A5 JP 2021511042A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide according
- nucleotides
- length
- oligonucleotide
- antisense
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862617692P | 2018-01-16 | 2018-01-16 | |
| US62/617,692 | 2018-01-16 | ||
| PCT/US2019/013672 WO2019143621A1 (en) | 2018-01-16 | 2019-01-15 | Compositions and methods for inhibiting aldh2 expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021511042A JP2021511042A (ja) | 2021-05-06 |
| JP2021511042A5 true JP2021511042A5 (https=) | 2022-01-20 |
| JPWO2019143621A5 JPWO2019143621A5 (https=) | 2022-01-20 |
Family
ID=67302455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539274A Pending JP2021511042A (ja) | 2018-01-16 | 2019-01-15 | Ａｌｄｈ２発現を阻害するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11661603B2 (https=) |
| EP (1) | EP3710588A4 (https=) |
| JP (1) | JP2021511042A (https=) |
| KR (1) | KR20200109311A (https=) |
| CN (1) | CN111601891A (https=) |
| AU (1) | AU2019209324A1 (https=) |
| CA (1) | CA3086409A1 (https=) |
| IL (1) | IL275539A (https=) |
| MX (1) | MX2020007582A (https=) |
| WO (1) | WO2019143621A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019143621A1 (en) | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
| CA3135402A1 (en) * | 2019-04-04 | 2020-10-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| WO2020226960A1 (en) | 2019-05-03 | 2020-11-12 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| EP4244356A1 (en) | 2020-11-13 | 2023-09-20 | Dicerna Pharmaceuticals, Inc. | Chemical modifications for inhibiting expression of aldh2 |
| CN113174438B (zh) * | 2021-06-01 | 2022-07-26 | 中国科学院城市环境研究所 | Aldh2基因多态性检测试剂盒及检测方法 |
| CN114891808B (zh) * | 2022-06-21 | 2023-10-27 | 珠海丽凡达生物技术有限公司 | 编码ALDH2多肽的mRNA分子、应用及mRNA药物 |
| WO2024000237A1 (zh) * | 2022-06-29 | 2024-01-04 | 河南省农业科学院植物营养与资源环境研究所 | Iaa-po1基因在诱导平菇原基形成和平菇生长发育抗逆中的应用 |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| AU2023408479A1 (en) * | 2022-12-19 | 2025-05-01 | Arnatar Therapeutics, Inc | Advanced rna targeting (arnatar) |
| CN119082043A (zh) * | 2024-10-10 | 2024-12-06 | 张家界学院 | Aldh2稳定表达的细胞系、构建方法及应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032788A1 (en) | 1997-07-03 | 2003-02-13 | Thomas Jefferson University | Methods of inhibiting alcohol consumption |
| DE60030403D1 (de) * | 1999-08-30 | 2006-10-12 | Wisconsin Alumni Res Found | Herstellung von 3-hydroxypropionsäure in rekombinanten organismen |
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| US20050019915A1 (en) | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
| JP2005508196A (ja) | 2001-11-07 | 2005-03-31 | アプレラ コーポレイション | 核酸分析の汎用ヌクレオチド |
| EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US20050287570A1 (en) * | 2004-05-26 | 2005-12-29 | Wyeth | Probe arrays for expression profiling of rat genes |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| JP2012504389A (ja) * | 2008-09-22 | 2012-02-23 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | 修飾を有するｄｓＲＮＡによる遺伝子発現の特異的な阻害のための組成物および方法 |
| US8691971B2 (en) | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| AU2009336191B2 (en) | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| KR20120005240A (ko) | 2010-07-08 | 2012-01-16 | 한양대학교 산학협력단 | 제2알데하이드 탈수소효소의 발현을 억제하는 인공 마이크로 ｒｎａ 및 이의 이용 |
| US8999950B2 (en) | 2011-10-05 | 2015-04-07 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing aldehyde dehydrogenase |
| JP2015501155A (ja) | 2011-10-25 | 2015-01-15 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｇｃｃｒ発現のアンチセンス調整 |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| WO2015169973A2 (de) | 2014-05-09 | 2015-11-12 | Protagen Ag | Markersequenzen zur diagnose und stratifizierung von systemische sklerose patienten |
| JP2017522046A (ja) | 2014-06-06 | 2017-08-10 | ソルスティス バイオロジクス，リミティッド | 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 |
| JP7105065B2 (ja) | 2014-12-15 | 2022-07-22 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | リガンド修飾二本鎖核酸 |
| US10689647B2 (en) | 2015-05-08 | 2020-06-23 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA |
| JP7249080B2 (ja) | 2016-08-23 | 2023-03-30 | ディセルナ ファーマシューティカルズ インコーポレイテッド | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 |
| KR102350647B1 (ko) | 2016-09-02 | 2022-01-14 | 다이서나 파마수이티컬, 인크. | 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드 |
| JP7155239B2 (ja) | 2017-04-05 | 2022-10-18 | サイレンス・セラピューティクス・ゲーエムベーハー | 産物及び組成物 |
| EP4029942A1 (en) | 2017-04-05 | 2022-07-20 | Silence Therapeutics GmbH | Products and compositions |
| HRP20231063T1 (hr) | 2017-10-13 | 2023-12-22 | Novo Nordisk Health Care Ag | Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha |
| MX2020004897A (es) | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| CA3118327A1 (en) | 2017-11-13 | 2019-05-16 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of aldh2 in a cell |
| WO2019143621A1 (en) | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
| CA3135402A1 (en) | 2019-04-04 | 2020-10-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| EP4244356A1 (en) | 2020-11-13 | 2023-09-20 | Dicerna Pharmaceuticals, Inc. | Chemical modifications for inhibiting expression of aldh2 |
-
2019
- 2019-01-15 WO PCT/US2019/013672 patent/WO2019143621A1/en not_active Ceased
- 2019-01-15 EP EP19741676.1A patent/EP3710588A4/en not_active Withdrawn
- 2019-01-15 AU AU2019209324A patent/AU2019209324A1/en not_active Abandoned
- 2019-01-15 MX MX2020007582A patent/MX2020007582A/es unknown
- 2019-01-15 CA CA3086409A patent/CA3086409A1/en active Pending
- 2019-01-15 KR KR1020207020150A patent/KR20200109311A/ko not_active Ceased
- 2019-01-15 CN CN201980008527.XA patent/CN111601891A/zh active Pending
- 2019-01-15 JP JP2020539274A patent/JP2021511042A/ja active Pending
- 2019-01-15 US US16/961,918 patent/US11661603B2/en active Active
-
2020
- 2020-06-21 IL IL275539A patent/IL275539A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021511042A5 (https=) | ||
| JP2021521796A5 (https=) | ||
| JP2019214587A5 (https=) | ||
| JPWO2019204021A5 (https=) | ||
| JP2023103244A5 (https=) | ||
| JP2020529197A5 (https=) | ||
| JP2021518125A5 (https=) | ||
| JP2021006029A5 (https=) | ||
| CN117701562A (zh) | 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法 | |
| JP2009514877A5 (https=) | ||
| JP2021533804A5 (https=) | ||
| JP2007529224A5 (https=) | ||
| JP2018530529A5 (https=) | ||
| CN108513588A (zh) | Kras表达的调节剂 | |
| JP2023068035A5 (https=) | ||
| JP2022503850A (ja) | 産物及び組成物 | |
| JP2022514657A (ja) | Ｈｓｄ１７ｂ１３発現のモジュレータ | |
| JPWO2022032288A5 (https=) | ||
| JPWO2019143621A5 (https=) | ||
| JP2021517826A5 (https=) | ||
| JPWO2023086864A5 (https=) | ||
| JPWO2019193144A5 (https=) | ||
| JP2021517909A5 (https=) | ||
| WO2025201416A1 (zh) | 靶向抑制素亚单位βE的核酸及其用途 | |
| JPWO2022031847A5 (https=) |